Close Menu

Out of Academia

In a blog post at DeviceRandom, Massimo Sandal says why he left not only his chemistry postdoc at the University of Cambridge, but also why he chose to leave academia altogether. While he wasn't overly optimistic about his most recent research project, Sandal says he chose to leave the lab because he thinks there are problems within the "practice of science itself." While he says he still loves science, he's not so enamored with the high-stakes "competition for funding and positions" he's seen within it.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.